Daraxonrasib phase 3 data raise stakes in pancreatic cancer

Revolution Medicines is leaning into what may be one of the most consequential pancreatic cancer datasets presented at ASCO 2026: phase 3 RASolute 302 results showing daraxonrasib substantially outperformed standard chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The company’s topline release in April 2026 reported median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy in the overall study population, and the full dataset was presented in a plenary session on May 31, 2026, with simultaneous publication in The New England Journal of Medicine. (ir.revmed.com)

The backdrop here is years of frustration in pancreatic cancer, where second-line treatment has offered limited benefit and survival remains poor. According to The ASCO Post, standard second-line regimens have typically delivered median progression-free survival of about 3 to 4 months and median overall survival of 6 to 7 months. Daraxonrasib entered this setting with momentum from earlier-phase data in RAS-mutated disease, including a phase 1/2 study published in May 2026 in NEJM, and with the broader thesis that directly targeting activated RAS signaling might finally move the needle in one of oncology’s hardest tumors. (ascopost.com)

RASolute 302 was designed as a global, randomized, registrational phase 3 study comparing once-daily oral daraxonrasib with investigator’s choice cytotoxic chemotherapy in previously treated metastatic PDAC. Revolution Medicines said the first interim analysis was sufficient to render the progression-free and overall survival endpoint results final. The ASCO Post reported the trial enrolled 500 patients across North America, Europe, and Asia, with 248 assigned to daraxonrasib and 252 to chemotherapy. Median progression-free survival reached 7.2 months overall with daraxonrasib versus 3.6 months with chemotherapy, and the drug was reported to produce fewer serious adverse events, with a manageable safety profile and no unexpected findings. (ir.revmed.com)

A key point in the company’s messaging is breadth. Revolution Medicines has emphasized that daraxonrasib is a multi-selective RAS(ON) inhibitor intended to address a broad range of oncogenic RAS drivers, not just one KRAS allele. The trial included patients with a range of RAS variants, as well as some without an identified RAS mutation, and Dana-Farber’s Brian Wolpin said the survival benefit was seen regardless of RAS mutation status. That broad activity is part of why the results are drawing attention beyond a single niche biomarker subgroup. (ir.revmed.com)

Outside reaction has been unusually strong. Wolpin called the findings “a very important advance” that he expects to be practice-changing, and Dana-Farber said the results support daraxonrasib as a new standard of care in the second-line metastatic setting. In separate commentary to The ASCO Post, Colin Weekes, MD, PhD, described the ability to target RAS in pancreatic ductal adenocarcinoma as “a game-changing situation” and said median overall survival exceeding one year in the second-line setting is unprecedented. ApexOnco also reported that ASCO chief medical officer Julie Gralow characterized the result as “a grand slam,” underscoring how unusual the reception has been for a pancreatic cancer plenary. (ir.revmed.com)

Why it matters: For veterinary professionals, this is still human medicine, but it’s relevant because it reflects a broader shift in oncology drug development that often spills into comparative research and clinical expectations. The important signal isn’t just that one pancreatic cancer drug worked. It’s that a pathway long viewed as difficult to drug may now be yielding clinically meaningful, survival-extending therapies, including oral agents with potentially more manageable toxicity than IV chemotherapy. For veterinary oncologists and general practitioners following precision medicine, that reinforces the value of molecular profiling, translational trial design, and careful conversations with pet parents about where targeted therapy is advancing quickly, and where evidence in veterinary patients still lags. (ascopost.com)

There are also concrete regulatory and access implications. Revolution Medicines has said it plans global submissions, including a future FDA new drug application under a Commissioner’s National Priority Voucher. Separately, the FDA announced on May 1, 2026, that it had issued a “safe to proceed” letter allowing an expanded access treatment protocol for daraxonrasib in previously treated metastatic PDAC. That creates a near-term bridge for some patients while formal review plays out. (ir.revmed.com)

What to watch: The next milestones are regulatory filings, details on how quickly expanded access is implemented in practice, and whether the ongoing first-line RASolute 303 study can extend daraxonrasib’s role beyond second-line disease. (ir.revmed.com)